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Abstract 
Background: The PAST-BP trial found that using a lower systolic blood pressure (SBP) 
target (<130 mmHg or lower versus < 140mmHg) in a primary care population with 
prevalent cerebrovascular disease was associated with a small additional reduction in blood 
pressure (2.9 mmHg).  
Objectives: To determine the cost effectiveness of an intensive systolic blood pressure target 
(<130mmHg or lower) compared with a standard target (<140mmHg) in people with a 
history of stroke or transient ischaemic attack 
Perspective: UK National Health Service (NHS) and Personal Social Services (PSS) 
Setting: People with a history of stroke or transient ischaemic attack (TIA) on general 
practice stroke/TIA registers in England. 
Methods: A Markov model with a one year time cycle and a 30 year time horizon was used to 
estimate the cost per quality adjusted life year (QALY) of an intensive target versus a 
standard target. Individual patient level data were used from the PAST BP trial with regard to 
change in blood pressure and numbers of primary care consultations over a 12 month period. 
Published sources were used to estimate life expectancy, and risks of cardiovascular events 
and their associated costs and utilities.  
Results: In the base-case results, aiming for an intensive blood pressure target was dominant, 
with the incremental lifetime costs being £169 lower per patient than for the standard blood 
pressure target with a 0.08 QALY gain. This was robust to sensitivity analyses, unless 
intensive blood pressure lowering reduced quality of life by 2% or more.  
Conclusion: Aiming for a systolic blood pressure target of < 130mmHg or lower is cost 
effective in people who have had a stroke/TIA in the community, but it is difficult to separate 
out the impact of the lower target from the impact of more active management of blood 
pressure.  
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Background 
Stroke is a major cause of morbidity and mortality in the UK. There are approximately 
110,000 strokes per year in England and around 300,000 people living with moderate to 
severe disabilities as a result of stroke. 
1
 After a first stroke, patients are at high risk of a 
recurrent event: for every 1000 first strokes, 240 will have a recurrent cardiovascular disease 
(CVD) event within five years of the first episode, of which, 180 would be a stroke and 29 of 
these would be fatal. 
2
 In 2008-09, the direct care cost of stroke was £3 billion annually, 
within a wider economic cost of about £8 billion. Without preventative action, there is likely 
to be an increase in strokes as the population ages.
1
 Therefore, secondary prevention has a 
major potential role to play in reducing both morbidity and costs of stroke care. 
There is controversy over how intensively to lower blood pressure in people who have had a 
stroke, with different international guidelines recommending different target blood 
pressures,
3 4
  and uncertainty over the applicability of the current evidence base for blood 
pressure reduction after stroke to people with a history of transient ischaemic attack (TIA) or 
stroke in community populations.
5
 
6
 A systematic review of the effect of intensive blood 
pressure lowering in populations including those with a history of stroke found that more 
intensive blood pressure lowering does lead to reduced risk of major cardiovascular events, 
6
 
and the recent SPRINT trial, all be it in a population without history of stroke, found that 
intensive blood pressure lowering reduced major cardiovascular events and all cause 
mortality. 
7
  Therefore, there is renewed interest in strategies to intensively lower blood 
pressure in high risk populations, such as those with a history of stroke or TIA. The 
Prevention AfTer Stroke – Blood Pressure (PAST-BP) randomised controlled trial compared 
the impact of an intensive systolic blood pressure target (<130mmHg or 10mmHg reduction 
from baseline if this was < 140mmHg) with a standard target (<140mmHg) in people with a 
history of stroke or TIA recruited from primary care.
8
 The trial involved active management 
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in all patients, and found that this led to important reductions in blood pressure in both arms.
9 
The more intensive target was associated with only a small additional reduction in blood 
pressure (2.9mmHg), which raises the question as to whether such an intensive target is cost 
effective.  
Here, we report the results of a model-based cost-utility analysis which extrapolates the 
results of the PAST-BP trial
9
 to estimate the long term cost-effectiveness of intensive blood 
pressure lowering targets after stroke/TIA in a primary care population, compared to a 
standard target.    
Methods 
A Markov model was constructed to estimate the long-term cost-effectiveness, in terms of the 
cost per quality adjusted-life year (QALY) gained, of an intensive target strategy versus a  
standard target strategy for blood pressure lowering in people with history of stroke or TIA. 
The model was developed using TreeAge Pro Suite 2012 software (TreeAge Software Inc, 
Williamstown, MA, USA). The analysis was conducted from a UK National Health Service 
(NHS) and Personal Social Services (PSS) perspective. 
10
 
The model had a time cycle of one year with a 30-year time horizon (i.e. lifetime). The base-
case analysis considered a cohort similar to that recruited to the PAST-BP trial (aged 70 years 
old, 41% female).  Baseline characteristics for important potential confounders were similar 
in both arms.
9
 Movements between model health states were defined by transition 
probabilities, which represented the risk of experiencing an event within a year time cycle.  
Long term costs and health outcomes were assessed by attaching estimates of costs and 
utilities to the model health states. QALYs were calculated by multiplying life expectancy by 
the health state utility. Cost-effectiveness was expressed as cost per additional QALY gained. 
The structure of the Markov model is shown in Figure 1.  
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Individual patient level data were used from the PAST-BP trial
9
 supplemented by parameter 
estimates from published studies (Table 1). In the PAST-BP trial
9
 participants were recruited 
from stroke/TIA registers in English general practices during 2009-2011 and randomised to 
an intensive blood pressure target (<130mmHg or a 10mmHg reduction if baseline pressure 
<140mmHg) or a standard systolic blood pressure target (<140 mmHg).  Over one year, 
mean systolic blood pressure dropped by 16.1 mmHg in the intensive target arm and by 12.8 
mmHg in the standard arm (adjusted difference between groups 2.9 mmHg, p = 0.03).  For 
extrapolation beyond one year, we assumed that this difference in blood pressure was 
maintained.  
Model structure and inputs 
The cohort started in the initial health state ‘previous stroke/TIA’, and a patient could remain 
in the ‘previous stroke/TIA’ health state if they did not have a recurrent event or died. If a 
cardiovascular (CV) event or death occurred the patient moved to one of four possible health 
states: new stroke, myocardial infarction (MI), unstable angina (UA), or dead (see figure 1). 
Life tables were used to determine overall mortality dependent on age and gender, adjusted 
by CVD mortality.
11
  Death was attributed to either stroke, MI or other causes. After a CV 
event, individuals could survive from the event or die, with death from an event occurring 
within a year. Individuals that survived a CV event moved to the chronic health state for that 
event, where annual costs were incurred and quality of life was lower than in the ‘previous 
stroke/TIA’ state (Table 1). Individuals in a chronic health state were assumed to remain in 
that state for the rest of their lives unless they died from other causes. 
Annual transition probabilities determining the risk of a CV event were based on the results 
of the PROGRESS trial.
12
  Age-related risk reductions for coronary heart disease (CHD) and 
stroke associated with subsequent reductions in systolic BP observed in the PAST-BP trial 
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were obtained from Law et al (Table 1).
13
 The risk reduction for CHD was applied to both MI 
and UA. This approach has been previously used by other studies to convert a decrease in 
systolic BP to reductions in CHD and stroke risk.
14 15
 The probability of each CV event 
occurring, the risks of dying from stroke or MI and the increased risk of death once in a 
chronic health state incorporated in the model are shown in Table 1. Outcomes and costs 
were discounted at the standard annual rate of 3.5%.
10
  
Resource use and costs 
Costs are reported in UK pounds at 2011-12 unit prices, and discounted at 3.5% per annum.
10
  
Costs were derived from a combination of standard unit costs, NHS reference costs and 
previously published literature and were adjusted using the Hospital and Community Health 
Service index to the 2011/12 price year.
16
 Resource use and costs per patient were obtained 
from the PAST-BP trial and applied to the initial health state in the model.
9
 Costs for acute 
and chronic states were obtained from published sources.
17-20
 Costs considered over the 
lifetime of the model included the cost of antihypertensive drugs, consultation costs and 
subsequent cardiovascular events (Table 1).  
Utility values 
The primary outcome measure was quality adjusted life years (QALYs) (Table 1). The utility 
value for the starting ‘previous stroke/TIA’ health state in the model was obtained from the 
PAST-BP trial using the overall mean EQ-5D score at baseline. The EQ-5D is a widely used 
generic instrument that has been validated in many patient populations, and is recommended 
by the National Institute of Health and Care Excellence (NICE). 10 This was adjusted for age 
group using weights calculated from Ara et al
21
 which allowed a reduction in quality of life 
with increasing age to be incorporated in the model. Acute events were assumed to happen 
six months into a one year cycle.  Individuals stayed in that acute state for six months before 
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moving into a chronic health state. Utilities for the acute state were applied mid-way through 
the one-year cycle and those for the chronic state at the start of the next cycle following an 
acute event. Future health state utilities were estimated by multiplying the starting quality of 
life with that of the new health state. In the base-case analysis it was assumed that different 
intensities of blood pressure management had no effect on quality of life.
22
   
Analysis 
An incremental cost-utility analysis was undertaken. Probabilistic sensitivity analysis was 
based on 10,000 Monte Carlo simulations. A gamma distribution was fitted to the costs 
obtained from the PAST-BP trial. Beta distributions were used to model the probability of 
dying from any of the cardiovascular events as well as the uncertainty around the utility 
values. A cost-effectiveness plane
23
 and a cost-effectiveness acceptability curve (CEAC) 
were constructed, the latter to depict the probability of intensive BP lowering being more 
cost-effective compared to standard target at different cost per QALY willingness-to-pay 
thresholds.  
Uncertainty in the results of the model was assessed through sensitivity analyses. These 
involved varying the time horizon for the model; changing costs of disease and the initial cost 
for the intensive BP lowering arm by 30 percent; varying the effect size in the intensive BP 
lowering arm according to the 95% CI of the BP reduction difference achieved at 12 months; 
incorporating a quality of life decrement due to antihypertensive medication by reducing 
utility values (multiplicatively) for the initial health state in the intensive BP lowering arm by 
up to 10%.
21
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Results 
The base-case lifetime costs and QALYs are presented in Table 2. Compared to a standard 
BP target of 140mmHg SBP, intensive BP lowering was in a position of dominance, being 
cheaper and more effective. Intensive BP lowering was associated with average cost savings 
per patient of £169 and an additional 0.08 QALYs over 30 years.  
Figure 2 presents the cost-effectiveness plane comparing intensive BP lowering to standard 
target incorporating parameter uncertainty. The mean incremental costs and incremental 
effects (QALY gains) mostly lie in the North-East and South-East quadrants, indicating that 
intensive BP lowering is highly likely to be effective but with a large amount of uncertainty 
around its cost impact. The CEAC shows that if a decision maker has a willingness-to-pay of 
£20,000 per QALY gained, the likelihood of cost-effectiveness was 90% (figure 3). 
Sensitivity analysis  
Intensive BP lowering was cost-effective at £20,000 per QALY provided at least two years of 
treatment was given and became the dominant strategy after six
 
years (Web Table 1). Varying 
costs had little impact on the overall conclusion, but if the effect size was reduced to the 
lower bound of the 95% confidence interval for blood pressure reduction, intensive targets 
were no longer cost effective. If intensive blood pressure lowering is associated with a 2% or 
more reduction in quality of life, it is no longer effective, but remains the less expensive 
strategy because of reduction in cardiovascular events.  In this circumstance, the ICER 
suggests that standard targets are more cost effective (Web Table 1).  
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Discussion 
We found that a strategy of intensive blood pressure lowering in primary care as tested by the 
PAST BP trial is likely to be cost effective.  The extra initial costs of the intensive strategy 
are off-set by subsequent cost savings in terms of reduced cardiovascular events, such that the 
strategy is less expensive after six years, though there was much greater uncertainty around 
impact on costs as compared to impact on benefits (figure 2).  The intensive strategy is not 
cost effective if it is associated with a 2% or more reduction in quality of life. However, we 
have found in a previous trial that reductions in blood pressure of the order of magnitude seen 
in PAST BP were not associated with any effect on quality of life
24
 and there were no 
significant differences in adverse effects during the trial.
9
 This analysis assumes that the 
difference in blood pressure between the arms is maintained over time: the sensitivity 
analysis suggested that the ICER remains below £20,000/QALY provided the time horizon is 
at least 2 years. Furthermore, there is evidence from the SPS3 trial, which involved different 
targets for blood pressure in people with a history of lacunar stroke, that differences between 
arms were maintained up to eight years after randomisation.
25
   
PAST-BP was not powered to detect differences in cardiovascular events between arms, and 
so the impact of observed blood pressure reductions was estimated by applying these to the 
results of a systematic literature review.
13
  Recent evidence reinforces the likelihood that 
blood pressure reductions are indeed likely to lead to a reduction in risk of cardiovascular 
events. 
6
 While this evidence was not restricted to people with previous stroke, the relative 
reductions in cardiovascular risk associated with reduction in BP appears to be similar in 
people with and without existing cerebrovascular disease.
26
  
Our results are consistent with the results of a cost-effectiveness analysis based on the 
PROGRESS trial, which found treating people with cerebrovascular disease was cost-
10 
 
effective, with a cost per QALY of £6,927 over four years.
27
 Whereas our analysis found long 
term treatment to be dominant, the PROGRESS trial, found long term treatment remained 
more expensive than standard care. It is likely that this difference in costs reflects changes in 
drug prices since the PROGRESS economic analysis was performed. Our sensitivity analysis 
(see Web Table 1) showed that a 30% increase in the initial cost of intensive blood pressure 
lowering resulted in the intensive target arm becoming more expensive than the standard care 
arm. A change of this magnitude is plausible given that, for example, perindopril now costs 
£1.72 per month, as opposed to £10.95 as applied in 2005.
27 28
 
Strengths and limitations 
This study used cost and outcome data from a primary care based pragmatic randomised 
controlled trial (RCT) in patients with a past history of stroke or TIA.
9
 The use of a Markov 
model overcame limitations associated with within-trial analyses, specifically allowing the 
modelling of effects and costs on long-term events and the assessment of the long term cost-
effectiveness beyond the trial period.  
The model did not include recurrence of CV events beyond the first event. However, as the 
intensive lowering strategy was more effective and therefore likely to reduce CV risk, then 
this model simplification is likely to have produced more conservative model results.   
Linked to this, an additional limitation derives from the nature of Markov models. These 
assume that the probability of an individual moving to any given health state in one time 
period depends only on their current health state. Therefore a patient’s outcomes and costs 
are assumed to depend only on current health state, and this may underestimate overall costs 
and overestimate health outcomes for those who have suffered more than one event. Again, 
this is likely to have reduced the apparent cost effectiveness of intensive blood pressure 
lowering.  
11 
 
The PAST-BP trial did not have a ‘usual care’ arm – rather it compared two active 
management strategies, one to an intensive target, one to a standard target. As a result, the 
cost effectiveness analysis can only compare these two active strategies – it cannot examine 
the cost effectiveness of moving from usual care to active management.   
Clinical implications 
This analysis suggests that intensive blood pressure lowering in a post-stroke population in 
primary care is likely to be cost effective, despite the relatively small reduction in systolic 
blood pressure with which it is associated.  However, comparison of achieved blood pressure 
in the control group with less active BP management suggests that it is also likely that active 
management of blood pressure is more important than the target that is used.
9 24
 Therefore, it 
is difficult to determine from this economic analysis whether the priority should be to 
promote systolic targets less than 130mm Hg, or to promote more active management of 
blood pressure. The overall conclusion from this work is that interventions lowering blood 
pressure post stroke are likely to be cost-effective provided that they can be achieved without 
excessive additional cost or impact on quality of life. Intensive lowering of blood pressure in 
primary care appears to be one such option. 
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Figure 1 Markov model 
 
Note: The Markov model in this figure is only being displayed for the “Intensive Blood 
Pressure Lowering” strategy. The standard target strategy is identical. Similarly, the model is 
identical at every node ending with green circles. Final outcomes (shown as red triangles) are 
survival and death.  
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Table 1 Model parameters  
Parameter Value 
Distribut
-ion Source 
Reduction in systolic blood pressure at 12 months (mm Hg) 
Intensive BP lowering 16.1  
PAST-BP trial 
9
 
Standard target 12.8  
12 months difference 
between groups (95% 
CI) -2.9 (-5.7, -0.2)  
Annual event probabilities 
Stroke    
60 - 69 years old 0.0348  
PROGRESS & NICE, Lipid 
Modification Guidelines
12 18
 
70 - 79 years old 0.0589  
80 - 89 years old 0.0713  
Myocardial Infarction (MI) and Unstable Angina (UA) 
60 - 69 years old 0.0139  
PROGRESS & NICE, Lipid 
Modification Guidelines
12 18
 
70 - 79 years old 0.0232  
80 - 89 years old 0.0232  
Age-related relative risks at 12 months for intensive and standard BP lowering‡ 
MI and UA - Intensive BP lowering 
60 - 69 years old 0.62 [0.59, 0.65]  
PAST-BP Trial & Law et al 
9 
13
 
70 - 79 years old 0.68 [0.63, 0.70]  
80 - 89 years old 0.74 [0.69, 0.77]  
Stroke – Intensive BP lowering 
    
60 - 69 years old 0.52 [0.47, 0.56]  PAST-BP Trial & Law et al 
9 
15 
 
70 - 79 years old 0.58 [0.54, 0.63]  
13
 
80 - 89 years old 0.74 [0.68, 0.78]  
MI and UA – Standard target 
60 - 69 years old 0.68 [0.65, 0.70]  
PAST-BP Trial & Law et al 
9 
13
 
70 - 79 years old 0.72 [0.69, 0.75]  
80 - 89 years old 0.78 [0.74, 0.81]  
Stroke – Standard target 
    
60 - 69 years old 0.59 [0.55, 0.63]  
PAST-BP Trial & Law et al 
9 
13
 
70 - 79 years old 0.65 [0.61, 0.68]  
80 - 89 years old 0.78 [0.73, 0.82]  
Utilities for the initial health state 
Intensive BP lowering and Standard target 
 
60-69 years old 0.7241 Beta 
PAST-BP trial 
9
 70-79 years old 0.6631 Beta 
80-89 years old 0.6362 Beta 
Utilities for acute disease * 
Unstable angina (UA) 0.77 Beta 
NICE, Lipid Modification 
Guidelines 
18
 
Myocardial Infarction 
(MI) 0.76 Beta 
Stroke 0.63 Beta 
Dead 0.00  by definition 
Utilities for long term (chronic) disease* 
Unstable angina (UA) 0.88 Beta 
NICE, Lipid Modification 
Guidelines 
18
 
Myocardial Infarction 
(MI) 0.88 Beta 
16 
 
Stroke 0.63 Beta 
Probability of death from an event 
Fatal stroke 0.23 Beta Bamford et al 
29
 
Fatal myocardial 
infarction (MI)    
60 - 69 years old 0.23  
ONS, Deaths Registry 2011 
& Kerr et al
11 30
 
70 - 79 years old 0.39  
80 - 89 years old 0.52  
Annual cost of consultation per patient (UK £) - Intensive BP lowering 
GP consultations 86 
 
PAST-BP Trial & Curtis 
9 16
 
PN consultations 35 
 Annual cost of consultation per patient (UK £) - standard target 
GP consultations 50 
 
PAST-BP Trial & Curtis 
9 16
 
PN consultations 29 
 Average cost of hypertensive drugs per patient £ per year** 
Intensive BP lowering 23 
 
BNF 2012 
28
 
Standard target 20 
 Cost for the initial state £ per year 
Intensive BP lowering 144 Gamma PAST-BP trial, Curtis, BNF 
2012 
9 16 28
 Standard target 100 Gamma 
Costs of acute disease £ one-off cost 
Stroke 11020 Gamma Youman et al
19
 
MI 5487 Gamma Palmer et al
20
 
Unstable Angina 3292 Gamma Assumed 60% of MI 
17 
 
Costs for long-term (chronic) disease £ per year 
Stroke 2721 Gamma Youman et al
19
 
MI 572 Gamma 
NICE, Lipid Modification 
Guidelines 
18
 
Unstable Angina 572 Gamma 
NICE, Lipid Modification 
Guidelines 
18
 
‡ Relative risk comparing blood pressure after treatment with baseline blood pressure 
* These figures are multiplied by initial health state utility to estimate new health state utility 
** Annual cost of drugs was calculated on the basis of commonest drug and dose per drug 
group per arm at 6 and 12 months 
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Table 2 Base-case result: lifetime costs and outcomes per patient 
 
Costs (£) QALYs 
Incremental 
cost (£) 
Incremental 
QALYs 
ICER  
(£ per 
QALY) 
Standard target       9,889  7.4719 
   Intensive BP 
lowering       9,720  7.5539 - 169  0.082  Dominant  
 
Figure 2 Incremental Cost-Effectiveness Plane comparing the intensive BP lowering strategy 
vs. standard target strategy or usual care 
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Figure 3 Cost-Effectiveness Acceptability Curve (CEAC) for the intensive BP lowering 
model showing the probability that the intervention is cost-effective 
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Web Table 1 Results of sensitivity analysis 
 
Costs (£) QALYs 
Incremental 
cost (£) 
Incremental 
QALYs 
ICER 
(£/QALY) 
Varying time horizon 
20 years  
     
Standard target 
       
8,962  7.1032 
   Intensive BP 
lowering 
        
8,794  7.1762 -168 0.0729 Dominant 
10 years  
     
Standard target 
       
5,092  5.1861 
   Intensive BP 
lowering 
        
5,012  5.2191 -80 0.0329 Dominant 
7 years  
     
Standard target 
       
3,387  
      
4.0737  
   Intensive BP 
lowering 
        
3,362  
       
4.0916  -25 0.0179 Dominant 
6 years  
     
Standard target 
       
2,786  
      
3.6247  
   Intensive BP 
lowering 
        
2,779  
       
3.6381  -7 0.0134 Dominant  
3 years  
     
Standard target 1,270 2.0192 
   
Intensive BP 
lowering 1,286 2.0225 15 0.0034 4,590 
2 years  
     Standard target         834  1.3954
   Intensive BP 
lowering         850  1.3967 15 0.0012 11,707            
1 year  
     
Standard target 
          
409  0.7233 
   Intensive BP 
lowering 
           
419  0.7234 10 0.00007 141,231 
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Varying acute and chronic costs simultaneously 
30 percent decrease  
Standard target 
        
7,173  7.4719 
   Intensive BP 
lowering 
        
7,177  7.5539 4 0.0820 44 
30 percent increase  
Standard target 
        
12,604  7.4719    
Intensive BP 
lowering 
        
12,263 7.5539 -341 0.0820 Dominant 
      
30 per cent increase in the initial cost for the Intensive BP lowering arm  
Standard target 
        
9,889  7.4719 
   Intensive BP 
lowering 
        
10,093  7.5539 204 0.0820 2,492 
Varying the intensive BP lowering arm according to the 95% CI of the BP reduction 
difference achieved at 12 months 
0.2 points difference  
Standard target 
        
9,889  7.4719 
   Intensive BP 
lowering 
        
10,188  7.4824 299 0.0104 28,613 
      5.7 points difference  
Standard target 
        
9,889  7.4719 
   Intensive BP 
lowering 
        
9,345  7.6125 -543 0.1406 Dominant 
      
Reduction in quality of life due to antihypertensive medication in the intensive BP lowering 
arm 
1 percent reduction  
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Standard target 
        
9,889  7.4719 
   Intensive BP 
lowering 
        
9,720  7.4944 -169 0.0225 Dominant 
2 percent reduction  
Standard target 
        
9,889  7.4719    
Intensive BP 
lowering 
        
9,720  7.4349 -169 -0.0371 ** 4,552 
5 percent reduction  
Standard target 
        
9,889  7.4719    
Intensive BP 
lowering 
        
9,720  7.2562 -169 -0.2157 ** 782 
10 percent reduction  
Standard target 
        
9,889  7.4719    
Intensive BP 
lowering 
        
9,720  6.9584 -169 -0.5135 ** 328 
** These positive ICERs represent points in the south-west quadrant of the incremental cost-
effectiveness plane: they indicate a cost saving accompanied by a loss of QALYs. In each 
case, the ICER is below all recognised thresholds: if these were to be the true values, this 
would indicate that the cost saving was not worth making. 
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